Zhentong Powder Veterinary Grade API is a dry active pharmaceutical ingredient powder supplied for incorporation into tablets, injections, capsules, oral powders, granules, premixes, and solutions intended for veterinary use. The manufacturer assigns the product identifier ZT-VG-API and distinguishes a standard-milled model from a micronized model on the certificate of analysis. Each lot is released under a veterinary GMP framework aligned with VICH GL18 and the relevant manufacturing provisions of 21 CFR Part 211. The powder is not a finished dosage form and is not a feed additive; it is a controlled starting material. The release certificate documents identity, assay, related substances, residual solvents, elemental impurities, loss on drying, particle size distribution, bulk density, tapped density, and microbiological quality. These attributes are maintained because they directly control downstream process behaviour in high-speed tablet presses, dosator capsule machines, aseptic solution filling lines, and continuous premix blenders. The following sections define the model structure, specification logic, application-specific constraints, and points of difference from lower-purity or alternative-grade powders.

Specification Model and Release Criteria

Release specifications are aligned with general pharmacopoeial methods because the availability of a single harmonised monograph for this exact veterinary entity may vary by region. Identity is established by Fourier-transform infrared spectroscopy or high-performance liquid chromatography retention time. Assay is reported on an anhydrous, solvent-free basis. Related substances are reported as individual specified impurities, individual unspecified impurities, and total impurities under VICH GL18 principles. Residual solvents are controlled by the methodology of USP <467>; elemental impurities are controlled using the risk-assessment and testing framework of USP <232> and USP <233>. Loss on drying is determined by USP <731>. Particle size distribution is measured by laser diffraction using ISO 13320:2020 with D10, D50, and D90 recorded from the cumulative volume distribution. Bulk density and tapped density are measured by USP <616> to derive Carr Index and Hausner Ratio. Microbial enumeration and specified-objection tests follow USP <61> and USP <62>. Endotoxin testing for injectable applications follows USP <85>. The precise numerical limits are lot-specific and printed on the certificate of analysis; users must not apply generic limits from unrelated APIs.

In tableting and capsule filling, the standard-milled grade is used where particle size distribution is non-critical. Direct compression is viable only when the blended bulk powder exhibits a Carr Index below 25 and a Hausner Ratio below 1.25; values above these ranges require dry granulation or wet granulation to prevent weight variability and segregation. High-speed rotary tablet presses with forced feeders are used, and the powder must tolerate feeder shear without static build-up or excessive fines. Capsule operations on dosator machines require consistent tapped density because fill volume is constant; shifts in bulk density alter fill weight and content uniformity. Dry granulation by roller compaction is used when the API is moisture-sensitive or when the micronized grade is not required. Wet granulation with purified water, povidone, or starch paste is used for high-dose tablets, but residual moisture must be controlled below the lot-specific degradation threshold. The API should be pre-dried when ambient relative humidity exceeds 60% and the powder shows moisture uptake during open handling. In all solid-dose blending operations, geometric dilution with a compatible diluent such as lactose monohydrate or microcrystalline cellulose is mandatory.

What Changes When Zhentong Powder Is Processed for Injectable Solutions Instead of Premix Blends?

The micronized grade is specified for injectable solution manufacture because dissolution rate and filtration compatibility depend on particle size and surface area. Dissolution is performed in 316L stainless steel vessels with bottom-mounted agitation and jacket temperature control. The vehicle is Water for Injection; pH adjustment with dilute hydrochloric acid or sodium hydroxide may be required. Osmolarity is adjusted with sodium chloride or mannitol according to the target route of administration. For parenteral products, the final solution is passed through a sterilizing-grade membrane filter, typically 0.22 µm, and filled under Grade A aseptic conditions. The dry API is not sterile; terminal heat sterilization of the filled solution may be used only after compatibility and degradation studies confirm that potency and related substances remain within release limits. Endotoxin control follows USP <85>. Particulate matter is evaluated by the light obscuration method of USP <788>. Unlike premix blending, injectable processing does not use lactose or feed carriers because these are unacceptable for parenteral use. The API must be dissolved completely before filtration; undissolved particles reduce filter capacity and may indicate polymorphic or particle size problems. Stainless steel 316L passivated surfaces are preferred because rougher surfaces can retain residues and increase cleaning validation burden.

For oral granules, dry powders, and medicated premixes, the standard-milled grade is blended with carriers such as lactose monohydrate, calcium carbonate, rice hulls, or corn cob granules. A geometric dilution sequence is required when the active fraction is low to avoid segregation and hotspots. Blending is carried out in double-cone or V-blenders; continuous ribbon mixers are used for large-volume premix operations. Blend uniformity is assessed by withdrawing multiple sampling points and calculating relative standard deviation; a target not more than 5.0% RSD is frequently applied for potent actives, but acceptance limits must be established from process validation. Particle size distribution of the API and carrier must overlap sufficiently to reduce sifting segregation; if the API is too fine, it will adhere to blender walls and transfer lines. If the API is too coarse, it may segregate into the bottom of the blender. Premix formulations intended for incorporation into feed must be stable to feed mixing and pelleting; conditioning temperatures above 80°C require stability data demonstrating no degradation. The powder should not be combined with strongly acidic or strongly alkaline feed matrices without compatibility testing.

Differences from Feed-Grade Powders, Technical-Grade Actives, and Human APIs

The veterinary-grade API is differentiated from feed-grade powders by the depth of impurity control. Feed-grade materials are not routinely tested for related substances by VICH GL18 methods or for residual solvents by USP <467>. Technical-grade powders may contain process-related impurities that are unacceptable in oral or parenteral pharmaceutical forms. Elemental impurity control under USP <232>/<233> distinguishes the pharmaceutical grade from industrial or technical stock. For injectable applications, the endotoxin limit is a critical pharmaceutical specification; feed-grade material does not carry a bacterial endotoxin certificate. Human API monographs may be harmonised under ICH guidelines, while this product is manufactured and controlled under veterinary-specific guidance, primarily VICH GL18. The label must state “For veterinary use only” to prevent diversion into human pharmaceutical manufacturing. Differences also exist within the product line: the standard-milled model is optimised for solid oral dosage forms and premixes, whereas the micronized model is intended for injectable solutions and low-dose homogeneous blends. These models differ in particle size distribution and surface area; they should not be substituted without formulation revalidation.

When Micronization Is Required for Low-Dose Oral and Parenteral Forms

The micronized model is selected when dose uniformity in low-dose oral forms or dissolution in parenteral solutions becomes the controlling risk. Micronization increases surface area, reduces D90, and can improve dissolution rate, but also increases cohesiveness and electrostatic charging. In dry powder blending, micronized material may require a high-shear premix or a forced feeder to break agglomerates. In injection preparation, micronized powder dissolves faster in the vehicle, but it may also increase foaming and require vacuum degassing. For capsules and tablets, the micronized grade may be dry-granulated with a binder to improve flow; direct compression of micronized API alone is generally not feasible because of poor flow. Process decisions must be based on measured particle size distribution, not visual inspection. If the micronized grade is used in a premix, it should be layered onto a carrier by an adhesion mixing method to avoid dust formation.

Release testing requires high-performance liquid chromatography with diode-array detection for related substances, gas chromatography with headspace injection for residual solvents, and inductively coupled plasma mass spectrometry for elemental impurities. Karl Fischer titration is used for water determination where appropriate. Laser diffraction particle size analysis is performed with a wet or dry dispersion unit, and the appropriate refractive index must be validated for this API. Failure to standardise dispersion pressure can shift D90 values by several micrometres; therefore the analytical method must fix air pressure and feed rate. Stability and storage boundaries are set by the manufacturer’s stability programme. The powder is packaged in double polyethylene bags inside an aluminium composite pouch or fibre drum. It should be stored below 25°C and protected from moisture; relative humidity above 60% during open handling may require pre-drying. Incompatibilities with strong oxidising agents, strong alkalis, and certain metal ions should be assumed until forced-degradation data or excipient compatibility studies demonstrate otherwise. The product should not be mixed with amine-based or aldehyde-functional excipients without a forced-degradation assessment because these chemical groups can form adducts or degradation products. The dry powder must not be autoclaved. If terminal sterilisation of the finished injection is required, the formulated solution should be tested for assay, related substances, pH, colour, and particulate matter after sterilisation. No stability-indicating method should be considered valid unless it has been challenged with forced-degradation samples as described in VICH GL1 and VICH GL2. Published independent stability data for this specific configuration is limited; therefore each manufacturing site must generate its own data for the target dosage form.